Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them mdpi.com/3076184 #mdpicancers via Cancers MDPI #APL #leusm Amer Zeidan MBBS,MHS ‏عامر زيدان

Yale University Yale Cancer Center research advances presented at American Society of Hematology annual meeting m.yale.edu/czhm

Congrats to Jinsuke Nishino, Stephen Chung , Ashwin Kishtagari, MD, Wenhuo Hu on paper in Cancer Discovery today: use of non-selective b blockers impairs engraftment after allo hematopoietic cell transplants involving post-transplant chemo for GVHD prophylaxis aacrjournals.org/cancerdiscover…

New research YaleHematology shows early mortality in acute promyelocytic leukemia #APL is high but could improve w/timely diagnosis through education at a community level. pubmed.ncbi.nlm.nih.gov/39682277/ Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp Amer Zeidan MBBS,MHS ‏عامر زيدان Bewersdorf Lab Aram Bidikian

Honored to contribute to this study by Sean Morrison and team. In patients undergoing allogeneic transplantation and receiving post-transplant cytoxan, the use of non-selective β-blockers may significantly delay engraftment and worsen survival. aacrjournals.org/cancerdiscover…

And two of the world’s best looking future hematologists, dressed to kill at the Yale IM Traditional Residency Program Ball. Yale Internal Medicine Yale Hematology Oncology Fellows

Hail to the Chiefs 🎊🎉 Congratulations to Aram Bidikian, César Caraballo Cordovez, Charlie Marvil, Sierra Mendelson, Kylie Rostad, Christina Cotte, Rose Gedeon, and Emily-Rose Zhou. The future of our program is bright ❤️❤️ Mark D. Siegel Yale Internal Medicine Yale School of Medicine

The Department of Internal Medicine is pleased to announce its 2026 - 2027 chief residents. Congrats!

Congratulations and Welcome to Yale IM Traditional Residency Program! Can’t wait to meet everyone!

In 1978, Elizabeth Blackburn, a postdoc at Yale University published the structure of telomere (& later discovered telomerase & awarded Nobel prize). 45 years later, we Yale Cancer Center co-led the clinical trial that led to approval of first in class telomerase inhibitor (imetelstat) in #MDSsm

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…

Advances and Challenges in Management of Myelodysplastic Syndromes #MDSsm in our Yale Cancer Center open access free review led by our past 2 fellows Dr Jessica Stempel (now at Uni of Oregon) & Dr tariqkewan (now at Mayo Clinic) mdpi.com/3420652 #mdpicancers via Cancers MDPI